References

[1] Friedman S L, Neuschwander-Tetri B A, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies [J]. Nat Med., 2018, 24(7): 908-22.

[2] Zhou J, Zhou F, Wang W, et al. Epidemiological Features of NAFLD From 1999 to 2018 in China [J]. Hepatology, 2020, 71(5): 1851-64.

[3] Gofton C, Upendran Y, Zheng M H, et al. MAFLD: How is it different from NAFLD? [J]. Clin Mol Hepatol, 2023, 29(Suppl): S17-s31.

[4] Rong L, Zou J, Ran W, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD) [J]. Front Endocrinol (Lausanne), 2022, 13: 1087260.

[5] Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans [J]. Mol Metab, 2021, 50: 101122.

[6] Deprince A, Haas J T, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease [J]. Mol Metab, 2020, 42: 101092.

[7] Basaranoglu M, Basaranoglu G, Sentürk H. From fatty liver to fibrosis: a tale of "second hit" [J]. World J Gastroenterol, 2013, 19(8): 1158-65.

[8] Buzzetti E, Pinzani M, Tsochatzis E A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) [J]. Metabolism, 2016, 65(8): 1038-48.

[9] Trépo E, Valenti L. Update on NAFLD genetics: From new variants to the clinic [J]. J Hepatol, 2020, 72(6): 1196-209.

[10] Pingitore P, Romeo S. The role of PNPLA3 in health and disease [J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2019, 1864(6): 900-6.

[11] Pirazzi C, Valenti L, Motta B M, et al. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells [J]. Hum Mol Genet, 2014, 23(15): 4077-85.

[12] Basu Ray S. PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease [J]. Adipocyte, 2019, 8(1): 201-8.

[13] Gou Y, Wang L, Zhao J, et al. PNPLA3-I148M Variant Promotes the Progression of Liver Fibrosis by Inducing Mitochondrial Dysfunction [J]. Int J Mol Sci., 2023, 24(11).

[14] Basuray S, Wang Y, Smagris E, et al. Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis [J]. Proc Natl Acad Sci U S A, 2019, 116(19): 9521-6.

[15] Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease [J]. Nat Genet, 2008, 40(12): 1461-5.

[16] Cherubini A, Casirati E, Tomasi M, et al. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date [J]. Expert Opin Ther Targets, 2021, 25(12): 1033-43.

[17] Li G, Tang L J, Zhu P W, et al. PNPLA3 rs738409 C>G Variant Influences the Association Between Visceral Fat and Significant Fibrosis in Biopsy-proven Nonalcoholic Fatty Liver Disease [J]. J Clin Transl Hepatol, 2022, 10(3): 439-48.

[18] Pennisi G, Pipitone R M, Cammà C, et al. PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease [J]. Clin Gastroenterol Hepatol, 2021, 19(9): 1979-81.

[19] Yahoo N, Dudek M, Knolle P, et al. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation [J]. J Hepatol, 2023, 79(2): 538-51.

[20] Sunami Y, Rebelo A, Kleeff J. Lipid Droplet-Associated Factors, PNPLA3, TM6SF2, and HSD17B Proteins in Hepatopancreat-obiliary Cancer [J]. Cancers (Basel), 2021, 13(17).

[21] Kumashiro N, Yoshimura T, Cantley J L, et al. Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats [J]. Hepatology, 2013, 57(5): 1763-72.

[22] Sherman D J, Liu L, Mamrosh J L, et al. The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics [J]. bioRxiv, 2023.

[23] Cherubini A, Ostadreza M, Jamialahmadi O, et al. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women [J]. Nat Med, 2023, 29(10): 2643-55.

[24] Peter A, Kovarova M, Nadalin S, et al. PNPLA3 variant I148M is associated with altered hepatic lipid composition in humans [J]. Diabetologia, 2014, 57(10): 2103-7.

[25] Perttilä J, Huaman-Samanez C, Caron S, et al. PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis [J]. Am J Physiol Endocrinol Metab, 2012, 302(9): E1063-9.

[26] Wang Y, Kory N, Basuray S, et al. PNPLA3, CGI-58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice [J]. Hepatology, 2019, 69(6): 2427-41.

[27] Hoekstra M, Li Z, Kruijt J K, et al. The expression level of non-alcoholic fatty liver disease-related gene PNPLA3 in hepatocytes is highly influenced by hepatic lipid status [J]. J Hepatol, 2010, 52(2): 244-51.

[28] Schuster S, Cabrera D, Arrese M, et al. Triggering and resolution of inflammation in NASH [J]. Nat Rev Gastroenterol Hepatol, 2018, 15(6): 349-64.

[29] Arrese M, Cabrera D, Kalergis A M, et al. Innate Immunity and Inflammation in NAFLD/NASH [J]. Dig Dis Sci, 2016, 61(5): 1294-303.

[30] Giraldez M D, Carneros D, Garbers C, et al. New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology [J]. Nat Rev Gastroenterol Hepatol, 2021, 18(11): 787-803.

[31] Park J, Zhao Y, Zhang F, et al. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease [J]. J Hepatol, 2023, 78(1): 45-56.

[32] Marra F, TackE F. Roles for chemokines in liver disease [J]. Gastroenterology, 2014, 147(3): 577-94.e1.

[33] Nischalke H D, Lutz P, Bartok E, et al. The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu [J]. J Mol Med (Berl), 2019, 97(11): 1589-600.

[34] Njei B, Al-Ajlouni Y A, Ugwendum D, et al. Genetic and epigenetic determinants of non-alcoholic fatty liver disease (NAFLD) in lean individuals: a systematic review [J]. Transl Gastroenterol Hepatol, 2024, 9: 11.

[35] Angulo P, Kleiner D E, Dam-LarseN S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease [J]. Gastroenterology, 2015, 149(2): 389-97.e10.

[36] Bruschi F V, Tardelli M, Herac M, et al. Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH [J]. Liver Int, 2020, 40(5): 1098-110.

[37] Manchiero C, Nunes A, Magri M C, et al. The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C [J]. BMC Infect Dis, 2017, 17(1): 780.

[38] Gavril O I, Arhire L I, Gavrilescu O, et al. Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response [J]. Medicina (Kaunas), 2021, 57(11).

[39] Lindén D, Ahnmark A, Pingitore P, et al. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice [J]. Mol Metab, 2019, 22: 49-61.

[40] Vilar-Gomez E, Pirola C J, Sookoian S, et al. PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features [J]. Hepatology, 2022, 76(5): 1482-94.

[41] Younossi Z, Tacke F, Arrese M, et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis [J]. Hepatology, 2019, 69(6): 2672-82.

[42] Fang J, Yu C H, Li X J, et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications [J]. Front Cell Infect Microbiol, 2022, 12: 997018.

[43] Ore A, Akinloye O A. Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions [J]. Medicina (Kaunas), 2021, 57(8).

[44] Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact [J]. J Hepatol, 2018, 68(2): 268-79.

[45] Carr R M, Oranu A, Khungar V. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management [J]. Gastroenterol Clin North Am, 2016, 45(4): 639-52.

[46] Luukkonen P K, Porthan K, Ahlholm N, et al. The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans [J]. Cell Metab, 2023, 35(11): 1887-96.e5.

[47] Mantovani A, Pelusi S, Margarita S, et al. Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction [J]. Aliment Pharmacol Ther, 2023, 57(10): 1093-102.